The importance of matching for HLA-DPB1 in unrelated donor haematopoietic stem cell (HSC) transplantation is little understood. Most transplant centres do not, currently, prospectively match for DPB1, but emerging data show that DPB1 matching does play a role in determining outcome. We studied the impact of HLA-DPB1 matching on outcome in 143 recipients of T-cell depletion transplants, who matched with their respective unrelated donors (allelic level) at HLA-A, -B, -C, -DRB1 and -DQB1. Of those matched at DPB1, 47.2% (17/36) developed acute graft-versus-host disease (aGvHD) as compared to 66.3% (55/83) of those who were mismatched. This led to a 19.1% (95% CI 0.1-38.3%) increase in the chance of developing aGvHD in mismatched patients (P ¼ 0.049). Relapse of the original disease occurred in 51 recipients; 23 of 37 (62%) matched at both DPB1 alleles, 28 of 82 (34%) were mismatched at one or two DPB1 alleles. Thus, there was a significantly higher relapse rate (P ¼ 0.0011) in transplant recipients who matched at both DPB1 alleles. In conclusion, a donor/recipient DPB1 match was associated with a significantly lower incidence of aGvHD and a significantly higher incidence of disease relapse. This study provides further evidence for an immunogenic role of HLA-DPB1 in HSC transplants.
HLA-DPB1; acute graft-versus-host disease; disease relapse Haematopoietic stem cell transplantation (HSCT), using a volunteer unrelated donor, is a well-established treatment for a number of haematologic disorders. In this setting, a HLA match (to allele level) is the most important donor factor affecting transplant outcome. 1 The importance of the class I loci (HLA-A, -B and -C) and of the class II loci (HLA-DRB1 and -DQB1) have been studied extensively, by many groups, in large numbers of patient/donor pairs. [1] [2] [3] [4] The relative importance of each of these loci on transplant outcome, and complications, has varied according to different groups, but nevertheless the benefit of a complete HLA match is clear. HLA-DP is a third locus in the class II region of the major histocompatibility complex. The HLA-DP molecule consists of both an alpha and a beta chain, encoded by the DPA1 and DPB1 genes, respectively. The beta chain is highly polymorphic, with 99 alleles recognised and named to date. 5 Conversely, there is limited polymorphism in the alpha chain and very strong linkage between DPA1 and DPB1. The importance of this locus, as a transplantation antigen, is poorly understood. One of the reasons that this antigen has received less attention in the past (than the other HLA loci) is the lack of, or weak, linkage disequilibrium which is found between HLA-DP and the other class II loci. 6, 7 This is thought to result from a recombination 'hotspot' in the region of chromosome 6 between the HLA-DPA1 and DQB1 genes. 6 Thus, the probability of finding a donor who is matched at DP in addition to the other five HLA loci is small. A recent study has investigated the mismatch frequency of this locus, in sibling donors, and found it to be 5.31%. 8 HLA-DP incompatibility has previously been reported to be as high as 10.9% in siblings. 9 Studies, in unrelated donors, have investigated the probability of having a match at DP, when retrospective DNA typing on transplanted pairs has been performed, and the incidence of mismatching is reported at between 75 and 89%. [10] [11] [12] There is evidence that HLA-DP does play a role in immunogenicity, both in nontransplant and transplant studies. An association has been shown between certain DPB1 alleles and susceptibility to particular diseases. [13] [14] [15] [16] [17] [18] HLA-DP-specific T-cells have been isolated from skin biopsies at the onset of graft-versushost-disease (GvHD) in HLA-DP mismatched transplants. 19 It has also been reported that most leukaemic blasts are accessible to direct lysis by allogeneic HLA-DPspecific T cells, suggesting that these cells may also be responsible for an antileukaemic effect. 20 Although it was previously reported that DPB1 had no impact on the incidence of transplant complications, such as acute GvHD, (aGvHD), 21, 22 there has since emerged evidence that HLA-DPB1 does play a role in alloreactivity following HSCT. A study from Seattle, reporting 205 T-cell replete transplants performed for CML, found a significant increase in the risk of clinically severe aGvHD when HLA-DPB1 was mismatched. A single HLA-DPB1 disparity did not affect the severity of aGVHD, but the presence of two HLA-DPB1 disparities was associated with more severe aGvHD than in patients with no disparity. Mild aGvHD (grades 1-2) was not increased in recipients with one or two HLA-DPB1 disparities. There was, however, no survival advantage because of this locus demonstrated in the study. Relapse data or the use of donor lymphocyte infusions (DLI) was not reported. 11 Conversely, in a large study published by the National Marrow Donor Program (NMDP), reporting the effects of HLA class II disparities on clinical outcome in patients transplanted for CML, no effect of DPB1 mismatching on the risk of developing aGvHD was found. There was no association seen between DPB1 matching and haematological disease relapse, disease-free survival or overall survival. 4 HLA class I typing, however, was only performed at a serological level in this study, making it difficult to fully interpret these results.
A study from Australia reported a significantly beneficial effect on patient survival in patient/donor pairs who were matched for HLA-DPB1, and there was an increase in the severity of aGvHD in those pairs where a mismatch was present. Once again no relapse data is presented; hence the overall survival does not reflect disease-free survival. 10 As is becoming increasingly clear, from these and other studies, the influence of an individual locus on transplant outcome needs to be assessed in the background of otherwise HLA-matched (allele level) pairs, in order to remove any confounding effects that mismatches at these known loci may have had on outcome.
Patients, materials and methods

Study population
We included 143 patients transplanted between 6 September 1996 and 1 June 2001 in this study. The inclusion criteria were as follows: (i) stem cells provided by a volunteer unrelated donor to a recipient at a transplant centre in the United Kingdom, (ii) final results of retrospective high-resolution tissue typing (to allele level) in donor and recipient performed on stored blood samples, and (iii) donors and recipients were matched at both alleles for HLA-A, -B, -C, -DRB1, and -DQB1.
In view of the number of transplant centres from which patients were drawn, there was no homogeneity within this cohort with respect to disease type or stage, conditioning regimen or type of GvHD prophylaxis used. However, the large majority of the recipients (490%) received in vivo or in vitro T-cell depletion (TCD) (most commonly employing Campath antibodies, either 1-G or 1-H). Post-transplant immunosuppression was used in 86% of recipients (64% of these received cyclosporin A and methotrexate, and 32% cyclosporin A alone).
The median follow-up in this group of transplant recipients is 340 days (mean ¼ 419). The range is from 9 to 1684 days.
Although every attempt was made, in some cases full clinical data could not be obtained. For this reason, the numbers analysed for each outcome may differ from the total number studied.
The data was all held and collated using Filemaker Pro software (Filemaker Inc., Santa Clara, CA, USA).
HLA typing
All of the class I (HLA-A, -B and -C) and class II (HLA-DRB1, -DQB1 and -DPB1) antigens considered were analysed using reference strand-mediated conformation analysis (RSCA). 23 In view of the very strong linkage disequilibrium between HLA-DPA1 and -DPB1 10 and HLA-DQA1 and -DQB1, 24 the respective alpha loci were not considered in this study. Likewise, the degree of linkage disequilibrium between specific DRB1 and DRB3/DRB4/ DRB5 is high, 12 and these were also not considered. HLA-DPB1 alleles were identified using locus-specific polymerase chain reaction amplifications. Primers used for these amplifications were described in the 11th Histocompatibility Workshop. 25 All of the HLA-DPB1 alleles seen in this study were identifiable by RSCA. Only one allele (HLA-DPB1*5401) had not previously been characterised by RSCA, but the mobility seen for this allele was distinct, and the allele was confirmed by sequence-based typing.
Statistical analysis
All statistical analyses were performed using SPSS (v.10.0) software (SPSS Inc., Chicago, IL, USA). The association between variables was assessed using nonparametric Mann-Whitney U-tests and Kruskal-Wallis tests. Overall survival, relapse-free survival, chronic graft-versus-host disease (CGvHD) and disease relapse rates were analysed using Kaplan-Meier methods (1958) and were compared using the log-rank statistic. Further, to investigate possible factors associated with these outcomes, Cox's proportionalhazards models were used. As an exact time to the development of aGvHD was only infrequently reported, the incidence of this complication was analysed as a binary variable using logistic regression models.
Results
Demographic characteristics
Patient and donor characteristics are shown in Table 1 . The three groups are defined by the number of HLA-DPB1 alleles which the recipient possessed, which would be recognised as foreign by the graft, that is, potentially evoke an immunological reaction in the graft-versus-host (GvH) direction. Homozygous recipients scored zero in a GvH direction if the donor shared at least one allele and one if the donor had two disparate alleles. Heterozygous recipients scored one if the donor was homozygous for one allele and two if the donor was heterozygous for two different alleles.
Frequency of HLA-DPB1 alleles
Of the 99 HLA-DPB1 alleles recognised by the WHO Nomenclature Committee for factors of the HLA system, 5 we found 25 in the recipient population and 24 in the donor population (26 different alleles in total). HLA-DPB1*0401 was the most frequently observed allele (47%), followed by DPB1*020102 (10%), DPB1*0402 (9%), DPB1*0301 (8%), and DPB1*010101 (6%). In all, 76 (27%) of the samples were homozygous for HLA-DPB1 and 210 (73%) were heterozygous.
Of the 143 pairs, 28 (20%) shared complete DPB1 identity, 69 (48%) had a mismatch at one allele and 46 (32%) were mismatched at two alleles. When DPB1 compatibility was considered (ie a recipient allele, not shared by the donor, and therefore likely to stimulate a GvH reaction), 41 (29%) pairs were completely DPB1 compatible, 70 (49%) had an incompatibility at one allele, and 32 (22%) had an incompatibility at two alleles. The reason for the discrepancy between DPB1 identity and compatibility is the high percentage of DPB1 homozygous individuals seen.
Engraftment
We considered engraftment (defined as recovery of the neutrophil count to greater than 0.5 Â 10 9 /l on 2 consecutive days) in those recipients who survived beyond day 30 post-transplant. This included 126 pairs; of those missing, nine had died prior to day 30 and in seven no information on engraftment was provided. Five recipients failed to engraft. Three of these recipients died prior to day 80: however, the other two remained alive at the time of last assessment (at days 657 and 741, respectively). Both had CML and both received autologous stem cell rescue. Three were matched at both DPB1 alleles, one at one allele and one at two alleles.
In 114 pairs, data on time to engraftment were available. The median time to neutrophil engraftment was 21 days. In all, 50 of 114 (44%) recipients engrafted prior to day 20, and 64 of 114 (56%) engrafted after day 20. There was no association found between HLA-DPB1 disparity and the rate of engraftment in these transplant pairs (irrespective of the direction of mismatch).
aGVHD aGvHD was graded as none (grade 0), mild (grades 1-2) or clinically severe (grades 3-4). aGvHD data were available on 121 of the 143 patients. Of these, 74 (61%) developed aGvHD. In the vast majority of these (86%), this was reported as mild, grade 1-2 aGvHD. In two recipients, the grade was unknown and in eight (11%) the grade was reported as 3-4. When aGvHD was taken as an individual risk factor for death, in a univariate analysis, there was a significant difference (P ¼ 0.001) in overall survival between the three groups of patients (Figure 1 ). At the time of analysis, the survival was 49% in the group with no aGvHD, 70% in those with grade 1-2 disease, and 25% in those with grade 3-4 disease.
In the 36 recipients who had complete DPB1 identity, 19 (53%) had no aGvHD, 16 (44%) had mild aGvHD and only one (3%) developed clinically severe aGvHD. Among those 83 with either one or two DPB1 allele disparities, 28 (34%) had no aGvHD, 48 (58%) had mild aGvHD and seven (8%) had severe aGvHD (Table 2 ). Therefore, of those who were matched at DPB1, 47.2% (17/36) developed aGvHD as compared to 66.3% (55/83) of those who were mismatched. This led to a 19.1% (95% CI 0.1-38.3%) increase in the chance of developing aGvHD in the mismatched patients (P ¼ 0.049).
The effect of mismatching on the incidence of aGvHD was not more marked when considering a two DPB1 allelemismatched transplant, as compared to a one allelemismatched transplant.
The degree of mismatching for HLA-DPB1 does affect the severity of aGvHD. Clinically severe aGvHD was relatively uncommon in this cohort of largely T-celldepleted transplant recipients. aGvHD was reported to be severe in one of 36 (3%) recipients with complete DPB1 identity; in four of 56 (7%), one allele-mismatched pair and in three of 27 (11%), two allele-mismatched pairs. Although these numbers are small, there is a trend towards an increase in severity of aGvHD as the number of mismatches at DPB1 increases.
The recipient with complete DPB1 identity remains alive at day 1070 post-transplant (this recipient was transplanted for CML in first chronic phase, suffered disease relapse at day 348 and received DLI). All four recipients of one allelemismatched transplants have died. Two of these recipients went on to develop chronic GvHD, and both are reported to have died because of this complication. One recipient died early because of aGvHD and the fourth recipient died from infection.
Two of the two allele-mismatched recipients have died; one attributed to aGvHD and the other to veno-occlusive disease. The third recipient remains alive at day 558 (this recipient was transplanted for Hodgkin's disease in third complete remission).
In a multivariate logistic regression model the influence of other donor and recipient factors on the incidence of aGvHD were assessed (Table 3) . HLA-DPB1 mismatching remained significantly associated with aGvHD with an odds ratio of 3.28 (95% CI 1.15-9.3%; P ¼ 0.026). Younger donors (under the age of 30) also predicted for the development of aGvHD. Older patients (over 40) and those with CML had an increase in aGvHD of borderline significance.
cGvHD
Of the 143 pairs, 107 were alive at day 100 (75%) and therefore evaluable for cGvHD. In all, 103 pairs had data available on cGVHD, and of these, 47 (46%) are reported to have developed this complication. Of the 103, 46 recipients had relapsed and 30 of these had received DLI (we did not analyse the outcome dependent on the dosage or number of infusions which were given). The presence of aGvHD was reported in over half (65%) of the recipients who went on to develop cGvHD (in six cases this was reported to be grade 3 or 4 disease).
Of the pairs who developed cGvHD, 11 of 31 (35%) were matched at both DPB1 alleles, 36 of 72 (50%) were mismatched for either one or two DPB1 alleles.
This resulted in no significant difference in the occurrence of cGvHD between the DPB1-matched or -mismatched group (P ¼ 0.17, difference in proportions test). There was no survival disadvantage associated with the presence of cGvHD in this cohort of patients.
Disease relapse
The five recipients who received transplants for nonmalignant disease were excluded from the analysis of disease relapse. Relapse data were available on 119 pairs. Relapse was considered if the recipient had, at least, molecular evidence of recurrent disease. By the end of follow-up, 51 recipients had suffered disease relapse (43%); 23 of 37 (62%) were matched at both DPB1 alleles, 19 of 57 (33%) were mismatched at one DPB1 allele and nine of 25 (36%) were mismatched at both DPB1 alleles. In a univariate analysis, there was a significantly higher relapse rate (P ¼ 0.0011) in those transplant recipients who were matched at both DPB1 alleles ( Figure 2) ; however, no difference in a single allele mismatch compared to a two allele mismatch in preventing this complication.
The disease categories represented by those who relapsed are as follows: 29 of 45 (64%) recipients with CML, eight of 22 (36%) recipients with AML, five of 28 (18%) recipients with ALL, and nine of 24 (38%) recipients with other malignant diseases. Thus, in univariate analysis, when comparing disease groups, those with CML were at higher risk of disease relapse; whereas recipients with ALL appeared to be at lower risk of disease relapse ( Figure 3) . The difference in relapse rates between these groups was significant (P ¼ 0.0009). It is possible that CML is more sensitive to control by T cells than other leukaemias, which may form part of the explanation for this observation (in a heavily T-cell-depleted cohort). Other potential explanations for this are a borderline association between the disease subtype and the incidence of mismatching at DPB1 (Mann-Whitney U-test, P ¼ 0.071), with a greater percentage of recipients with CML being matched at DPB1 with their donors. In addition, the age group of the CML patients was much higher than that of the patients with ALL, a factor again linked with an increase in disease relapse. There was no apparent difference between the preparatory regimen used for these two disease subgroups (as regards both conditioning protocols and TCD). Of the 51 relapsed recipients, 22 died (43%), in 16 of whom death could be attributed to disease relapse. Of these, eight (36%) received DLI. Of the 29 recipients who remain alive, 21 (72%) received DLI. Thus, the recipients who received DLI had a significant survival advantage compared to those who did not (P ¼ 0.001). Approximately, two-thirds of the recipients responding to DLI (irrespective of DPB1 matching) had CML.
In a proportional-hazard regression model, the significant factors associated with an increased relapse rate were HLA-DPB1 identity, patient CMV serostatus and patient age greater than 40 (Table 4) . Disease stage was adjusted for and did not alter the importance of DPB1 identity (data not shown).
There was no association between the incidence of disease relapse and the presence of either aGvHD (P ¼ 0.9; 95% CI 16.0-21.4%) or cGvHD (log-rank test P ¼ 0.88).
Disease-free survival
At the end of the follow-up period, the disease-free survival, in this cohort of donor/recipient pairs, was 39% (55 of 141 recipients). Using Kaplan-Meier analysis, disease-free survival was significantly better in those who were mismatched for DPB1 (log-rank P ¼ 0.02), compared to those who were matched for DPB1. 
Survival
At the end of the follow-up period, the overall survival, in this cohort of donor/patient pairs, was 60% (84 of 141 recipients). There was no significant difference in overall survival noted (P ¼ 0.57) between those pairs who were matched and those who were mismatched for DPB1 (Figure 4 ). Of the 57 recipients who have died, 16 of 41 (39%) were matched at both DPB1 alleles and 41 of 100 (41%) were mismatched at either one or two DPB1 alleles. In a Cox proportional-hazards regression model, measuring overall survival and time, considering pretransplant factors including donor age, gender and CMV serostatus, recipient age, gender, CMV serostatus and disease, the only factors associated with a survival advantage are younger patient age and having a nonmalignant disease as the indication for transplantation. We have considered the cause of death in the groups depending on the presence or absence of a match at HLA-DPB1 (Table 5 ). There is no significant difference in the cause of death (Mann-Whitney U-test, P ¼ 0.353) between the two groups. As discussed, the incidence of relapse was higher in the recipients with complete HLA-DPB1 identity. However, when we analysed death in this cohort of recipients there was no significant difference in overall survival dependent on DPB1 matching (P ¼ 0.18). Despite the lack of statistical significance, we did note that none of the recipients who had complete DPB1 identity died because of GvHD. In contrast, five of the deaths in the mismatched cohort (12%) were attributed to GvHD as the primary cause. One recipient died on day 20 with grade 4 aGvHD, the other four experienced severe aGvHD as well as cGvHD with deaths ranging from days 176 to 632. Only one of these recipients experienced disease relapse (transplanted for AML in second complete remission), but did not receive DLI at any stage.
Discussion
This study adds further data in support of a biological role of HLA-DPB1 in haematopoietic stem cell transplants. We have found a significant effect of this locus on the incidence of both aGvHD and on disease relapse. The incidence of clinically significant GvHD, and death attributed to GvHD, is low in this cohort of patients. This is likely to be explained by the TCD, which was used in the majority of these transplants, and which has been shown to result in a decrease in the incidence of GvHD. 26 Despite this, we are able to detect a difference in the incidence of aGvHD in those pairs who have a mismatch at HLA-DPB1. There is also a trend towards an increase in severity of this complication if a mismatch is present.
There is controversy in the literature concerning the nature of the impact of DPB1 mismatches. A paper examining clinical outcomes has reported a threshold effect (ie two mismatched alleles resulting in a higher incidence of GvHD than one mismatched allele). 11 Although this effect is a nonsignificant trend in our study, this can perhaps be explained by the use of TCD and the consequent low incidence of this severe aGvHD in this cohort.
Conversely, in a paper which considers a functional assay for assessing the matching of DPB1 alleles, 27 it is suggested that the type of mismatch affects the relative responses (RR) in the mixed lymphocyte reaction (MLR) more than does the simple presence of a mismatch. In this study, one or two allele mismatches caused a similar increase in the RR in the MLR, with no significant difference between the two. This group has also shown an increase in severe GvHD in recipients who were negative compared to those who were positive for DPB1 alleles encoding glutamic acid at position 69. 10 There are also reports of a comparable effect at class I alleles; a recently published study found that a substitution at position 116 in the class I heavy chain increased the risk for aGvHD. 28 We are not able to confirm the observation, with regard to DPB1, in the present study.
Thus, in our group of transplant pairs, the presence of a mismatch at DPB1 predicts for the development of aGvHD. In this setting, it is more likely to be severe and more likely to result in death; however, if the aGvHD is mild this translates into a survival advantage. Thus, the presence of aGvHD per se is not detrimental to these transplant recipients and suggests that some degree of T-cell activation in a GvH direction is desirable. It is likely that additional factors are involved, which influence the severity of aGvHD in pairs that are mismatched for this locus. A larger cohort of recipients, with the possibility of subgroup analysis may help to answer this question. The incidence of disease relapse has been reported to be higher in recipients of T-cell-depleted transplants, 26 suggesting a graft-versus-leukaemia effect mediated, at least in part, by T cells. This effect, as in our study, has been noted to be most marked in those recipients transplanted for CML. In this cohort of transplant recipients, the incidence of disease relapse was 43%. Our observation that the incidence of disease relapse is significantly higher in the presence of complete DPB1 identity between recipient and donor, supports the role of DPB1 in allo-antigen presentation. The presence of either one or two allele mismatches were found to protect from this complication. An impact of HLA-DPB1 on disease relapse has not previously been reported. Few studies have reported this parameter, and those that have, found no correlation with the level of DPB1 matching. 3, 4 Interestingly, a study from the NMDP, 4 while not observing an increase in relapse rate in DPB1-matched transplant recipients, have reported an increase in disease relapse associated with DQB1 mismatching.
A mechanism for this is not postulated. A possible mechanism to explain the increase in relapse rate may be the presence of DPB1-specific T cells directed against leukaemic blasts (as has been previously reported 20 ). This group has shown that the majority of leukaemic cells express detectable levels of HLA-DP antigens. However, it is not only T cells that have been implicated in disease relapse. It has previously been shown that a mismatch at HLA-C locus is associated with protection against disease relapse. In conclusion, we have shown an increase in relapse rate, and a corresponding decrease in the incidence of aGvHD, in patient/donor pairs who are matched at HLA-DPB1 in addition to the other polymorphic HLA class I and class II loci. This supports the idea that DPB1 plays a role as an allo-antigen in HSCT, and is actively involved in both the GvH and the graft-versus-leukaemia effects. We do not see any significant difference in the overall survival because of DPB1 identity in these recipients, as it is likely that the deaths because of relapse in the matched cohort are balanced by the deaths because of GvHD in the mismatched cohort. Owing to the small numbers in this present study, it has not been possible to break the pairs down into smaller groups looking as specific disease categories or particular donor characteristics. It may be instructive to perform such analysis, in order to be able to predict the likely outcome of a DPB1 match in an individual transplant setting and, therefore, tailor the conditioning and GvHD prophylaxis to the individual. Functional studies are also required to better define the role of HLA-DPB1, as an antigenic molecule, in the transplant setting.
